Modulated Electro-Hyperthermia-Induced Tumor Damage Mechanisms Revealed in Cancer Models
/in Hyperthermia, International Publications /von 2020-08-29 / Int J Mol Sci 2020 Aug;21(17)Hexokinase inhibition using D-Mannoheptulose enhances oncolytic newcastle disease virus-mediated killing of breast cancer cells
/in Breast Cancer, International Publications, Newcastle Disease Virus /von 2020-08-28 / Cancer Cell Int 2020;20:420Clinical effects of curcumin in enhancing cancer therapy: A systematic review
/in Curcuma, International Publications /von 2020-08-24 / BMC Cancer 2020 Aug;20(1):791Interaction between Gut Microbiota and Curcumin: A New Key of Understanding for the Health Effects of Curcumin
/in Curcuma, International Publications /von 2020-08-19 / Nutrients 2020 Aug;12(9)The tumor microenvironment of colorectal cancer metastases: opportunities in cancer immunotherapy
/in Colorectal Cancer, Dendritic Cells, International Publications /von 2020-08-13 / Immunotherapy 2020 Aug;A dendritic cell multitasks to tackle cancer
/in Dendritic Cells, International Publications /von 2020-08-12 / Nature 2020 Aug;Oncolytic effects of Hitchner B1 strain of newcastle disease virus against cervical cancer cell proliferation is mediated by the increased expression of cytochrome C, autophagy and apoptotic pathways
/in Cervical Cancer, International Publications, Newcastle Disease Virus /von 2020-08-07 / Microb Pathog 2020 Oct;147:104438Synergy between hemagglutinin 2 (HA2) subunit of influenza fusogenic membrane glycoprotein and oncolytic Newcastle disease virus suppressed tumor growth and further enhanced by Immune checkpoint PD-1 blockade
/in Checkpoint-Inhibitors, International Publications, Newcastle Disease Virus /von 2020-08-07 / Cancer Cell Int. 2020;20:380Low Vitamin C Status in Patients with Cancer Is Associated with Patient and Tumor Characteristics
/in International Publications, Micronutrients /von 2020-08-05 / Nutrients 2020 Aug;12(8)
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies
- Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum
- Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution